Next Article in Journal
Correction: Griffith, D.M., et al. Novel Improved Synthesis of HSP70 Inhibitor, Pifithrin-μ. In Vitro Synergy Quantification of Pifithrin-μ Combined with Pt Drugs in Prostate and Colorectal Cancer Cells. Molecules 2016, 21, 949
Next Article in Special Issue
Antibiofilm Activity of Plant Polyphenols
Previous Article in Journal
Transdermal Permeation and Anti-Inflammation Activities of Novel Sinomenine Derivatives
Previous Article in Special Issue
Extract from Maize (Zea mays L.): Antibacterial Activity of DIMBOA and Its Derivatives against Ralstonia solanacearum
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessArticle
Molecules 2016, 21(11), 1562; doi:10.3390/molecules21111562

Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae

School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Korea
School of Life Science, Handong Global University, 558 Handong-ro, Buk-gu, Pohang 37554, Korea
Dong Wha Pharm., Ind. Co. Ltd., Anyang 31041, Korea
These authors contributed equally to this work.
Author to whom correspondence should be addressed.
Academic Editor: Diego Muñoz-Torrero
Received: 15 September 2016 / Revised: 1 November 2016 / Accepted: 9 November 2016 / Published: 17 November 2016
View Full-Text   |   Download PDF [1179 KB, uploaded 17 November 2016]   |  


Zabofloxacin is a novel fluoroquinolone agent that has potent activity against gram-positive pathogens. In this study, we confirmed that zabofloxacin showed the most potent in vitro and in vivo activities against drug-resistant Streptococcus pneumoniae. Among the fluoroquinolone compounds, zabofloxacin showed the most potent in vitro activity against clinical isolates of penicillin-sensitive S. pneumoniae (minimum inhibitory concentration, MIC90: 0.03 mg/L) and penicillin-resistant S. pneumoniae (MIC90: 0.03 mg/L). Against quinolone-resistant S. pneumoniae, zabofloxacin (MIC90: 1 mg/L) was more active than ciprofloxacin, sparfloxacin, and moxifloxacin; however, its activity was the same as that of gemifloxacin. The in vivo activity of zabofloxacin was most potent among the quinolone compounds tested against the systemic infection and respiratory tract infection models in mice. View Full-Text
Keywords: zabofloxacin; minimum inhibitory concentration; Streptococcus pneumoniae; in vivo zabofloxacin; minimum inhibitory concentration; Streptococcus pneumoniae; in vivo

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Park, H.-S.; Oh, S.-H.; Kim, H.-S.; Choi, D.-R.; Kwak, J.-H. Antimicrobial Activity of Zabofloxacin against Clinically Isolated Streptococcus pneumoniae. Molecules 2016, 21, 1562.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top